- Home
- MBIO vs BGMS Comparison
MBIO vs BGMS Comparison
Compare MBIO & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBIO | BGMS |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MBIO | BGMS |
|---|---|---|
| Price | $0.87 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 432.4K | 175.9K |
| Earning Date | 03-27-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.46 |
| 52 Week Low | $0.53 | $0.74 |
| 52 Week High | $7.00 | $100.75 |
Technical Indicators
Market Signals| Indicator | MBIO | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 37.36 |
| Support Level | $0.53 | $0.98 |
| Resistance Level | $1.10 | $1.06 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 66.13 | 38.43 |
Price Performance
Historical ComparisonAbout MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.